Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Glyscend Therapeutics released topline data for its polymer targeting type 2 diabetes and obesity today, with the hopes the candidate will have the same effects as bariatric surgery without complications from the invasive standard-of-care procedures.
BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers significant and clinically relevant reductions in postprandial glucose and body weight and support its advancement into a Phase 2b clinical trial.
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors